The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Dynavax Technologies Corp’s stock clocked out at $10.97, up 0.83% from its previous closing price of $10.88. In other words, the price has increased by $0.83 from its previous closing price. On the day, 1.51 million shares were traded. DVAX stock price reached its highest trading level at $11.095 during the session, while it also had its lowest trading level at $10.86.
Ratios:
To gain a deeper understanding of DVAX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.99. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 7.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.46.
Upgrades & Downgrades
In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Sell and sets its target price to $12 from $15 previously.
On February 01, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $20.
On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.JMP Securities initiated its Mkt Outperform rating on September 27, 2022, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when Myers Scott Dunseth bought 3,800 shares for $10.82 per share. The transaction valued at 41,116 led to the insider holds 35,004 shares of the business.
Deep Track Biotechnology Maste sold 1,094,994 shares of DVAX for $12,077,784 on Aug 21 ’25. The 10% Owner now owns 16,696,492 shares after completing the transaction at $11.03 per share. On Aug 22 ’25, another insider, Deep Track Biotechnology Maste, who serves as the 10% Owner of the company, sold 970,143 shares for $10.59 each. As a result, the insider received 10,273,814 and left with 15,726,349 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1288151936 and an Enterprise Value of 929559872. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.90 while its Price-to-Book (P/B) ratio in mrq is 2.41. Its current Enterprise Value per Revenue stands at 2.812 whereas that against EBITDA is 38.394.
Stock Price History:
The Beta on a monthly basis for DVAX is 0.93, which has changed by -0.15198755 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, DVAX has reached a high of $14.63, while it has fallen to a 52-week low of $9.20. The 50-Day Moving Average of the stock is 4.61%, while the 200-Day Moving Average is calculated to be 0.07%.
Shares Statistics:
It appears that DVAX traded 1.67M shares on average per day over the past three months and 1702900 shares per day over the past ten days. A total of 117.36M shares are outstanding, with a floating share count of 116.69M. Insiders hold about 0.62% of the company’s shares, while institutions hold 97.43% stake in the company. Shares short for DVAX as of 1763078400 were 13723263 with a Short Ratio of 8.20, compared to 1760486400 on 14199536. Therefore, it implies a Short% of Shares Outstanding of 13723263 and a Short% of Float of 17.59.
Earnings Estimates
As of right now, 1.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.5 and -$0.5 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is $0.33, with 1.0 analysts recommending between $0.33 and $0.33.
Revenue Estimates
In. The current quarter, 3 analysts expect revenue to total $80.26M. It ranges from a high estimate of $82.09M to a low estimate of $77.49M. As of. The current estimate, Dynavax Technologies Corp’s year-ago sales were $72.03MFor the next quarter, 3 analysts are estimating revenue of $84.68M. There is a high estimate of $94M for the next quarter, whereas the lowest estimate is $72.03M.
A total of 3 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $340.58M, while the lowest revenue estimate was $335.98M, resulting in an average revenue estimate of $338.75M. In the same quarter a year ago, actual revenue was $277.25MBased on 3 analysts’ estimates, the company’s revenue will be $392.42M in the next fiscal year. The high estimate is $417.12M and the low estimate is $360.14M.
